BioAtla, Inc.
BioAtla develops novel therapeutics with improved therapeutic index that are safer and more effective for treating cancer. Utilizing proprietary Conditionally Active Biologics (CAB) technology, the company creates targeted, efficacious, and lower-toxicity biologics for cancer treatment, with extensive patent coverage and a pipeline of first-in-class programs in clinical testing. The company emphasizes its commitment to innovation in antibody therapeutics, including bispecifics and antibody-drug conjugates, with ongoing clinical trials and research into tumor microenvironment and metabolic mechanisms such as the Warburg Effect and tumor acidity. BioAtla also values diversity, with 27% racial/ethnic diversity and a balanced gender representation on its board of directors.
Industries
Nr. of Employees
medium (51-250)
BioAtla, Inc.
11085 Torreyana Road, San Diego, California, USA
Patents
Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US-11976381-B2
View DetailsAnti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof
US-11897959-B2
View DetailsAnti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof
US-11879011-B2
View Details
Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US-11976381-B2
View DetailsAnti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof
US-11897959-B2
View DetailsAnti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof
US-11879011-B2
View DetailsProducts
Tumor-selective AXL-targeted antibody–drug conjugate
A conditionally active ADC directed to the AXL receptor designed to preferentially bind tumor tissue and deliver cytotoxic payloads for treatment of AXL-expressing solid tumors.
Tumor-selective ROR2-targeted antibody–drug conjugate
A conditionally active ADC directed to ROR2 designed to target multiple solid tumor types while minimizing normal tissue binding; included in expanded access considerations.
Tumor-microenvironment-restricted immune checkpoint antibody
An immune checkpoint antibody engineered for restricted activity in the tumor microenvironment to aim for checkpoint blockade efficacy with reduced systemic immune activation.
Tumor-selective bispecific T-cell engager (tumor antigen × CD3)
Bispecific engager formats that bind a tumor antigen and CD3 on T cells, engineered for tumor-selective activity to reduce systemic T cell activation while redirecting T-cell cytotoxicity.
Second-generation tumor-selective ADC with improved linker stability
A next‑generation ADC combining tumor-selective conditional antibodies with an improved linker system designed for greater stability and tumor-selective payload release.
Tumor-selective AXL-targeted antibody–drug conjugate
A conditionally active ADC directed to the AXL receptor designed to preferentially bind tumor tissue and deliver cytotoxic payloads for treatment of AXL-expressing solid tumors.
Tumor-selective ROR2-targeted antibody–drug conjugate
A conditionally active ADC directed to ROR2 designed to target multiple solid tumor types while minimizing normal tissue binding; included in expanded access considerations.
Tumor-microenvironment-restricted immune checkpoint antibody
An immune checkpoint antibody engineered for restricted activity in the tumor microenvironment to aim for checkpoint blockade efficacy with reduced systemic immune activation.
Tumor-selective bispecific T-cell engager (tumor antigen × CD3)
Bispecific engager formats that bind a tumor antigen and CD3 on T cells, engineered for tumor-selective activity to reduce systemic T cell activation while redirecting T-cell cytotoxicity.
Second-generation tumor-selective ADC with improved linker stability
A next‑generation ADC combining tumor-selective conditional antibodies with an improved linker system designed for greater stability and tumor-selective payload release.
Services
Operational sponsorship and conduct of early-phase oncology clinical trials including monotherapy and combination studies, adaptive platform participation, and biomarker-guided cohorts.
Contracted or in-house preclinical pharmacology, toxicology and manufacturing support to generate data packages for IND submissions across multiple modalities (ADCs, bispecifics, antibodies).
Development and validation of tumor antigen IHC assays and non-invasive liquid biopsy assays for patient selection and monitoring within clinical protocols.
Structuring and managing clinical collaborations, co-development agreements and supply partnerships to support combination studies and broaden development strategies.
Modeling services to develop population PK models and exposure–response safety analyses to inform dosing and safety risk assessment for clinical trials.
Evaluation and operational implementation of expanded access (compassionate use) requests under defined eligibility and supply constraints, including physician-directed request processing and safety monitoring requirements.
Operational sponsorship and conduct of early-phase oncology clinical trials including monotherapy and combination studies, adaptive platform participation, and biomarker-guided cohorts.
Contracted or in-house preclinical pharmacology, toxicology and manufacturing support to generate data packages for IND submissions across multiple modalities (ADCs, bispecifics, antibodies).
Development and validation of tumor antigen IHC assays and non-invasive liquid biopsy assays for patient selection and monitoring within clinical protocols.
Structuring and managing clinical collaborations, co-development agreements and supply partnerships to support combination studies and broaden development strategies.
Modeling services to develop population PK models and exposure–response safety analyses to inform dosing and safety risk assessment for clinical trials.
Evaluation and operational implementation of expanded access (compassionate use) requests under defined eligibility and supply constraints, including physician-directed request processing and safety monitoring requirements.
Expertise Areas
- Conditionally active biologics using protein-activated chemical switches
- Antibody-drug conjugate design and development
- Bispecific and multispecific T-cell engager development
- Tumor-microenvironment-targeted antibody engineering
Key Technologies
- Protein-activated chemical switches (PaCS) for conditional activation
- Conditionally active antibody engineering
- Antibody-drug conjugation and cleavable linker chemistries
- Bispecific T-cell engager platforms (tumor antigen × CD3 and tetravalent formats)
News & Updates
BioAtla announced its participation in the Jefferies Global Healthcare Conference, providing a corporate update and investor meetings.
BioAtla reported its Q2 2022 financial results, including clinical progress and operational updates on its programs BA3011, BA3021, and BA3071.
BioAtla announced its Q1 2022 financial results, clinical progress, and operational updates, including interim data from BA3011 in sarcoma.
BioAtla reported its 2021 financial results, clinical milestones, and pipeline progress, including updates on BA3011, BA3021, and BA3071.
BioAtla entered into a collaboration with Bristol Myers Squibb to investigate BA3011 and BA3021 in combination with Opdivo in solid tumors.
Discussion of the development of CAB antibodies that can be activated or inactivated under physiological conditions for cancer therapy.
BioAtla announced its participation in the Jefferies Global Healthcare Conference, providing a corporate update and investor meetings.
BioAtla reported its Q2 2022 financial results, including clinical progress and operational updates on its programs BA3011, BA3021, and BA3071.
BioAtla announced its Q1 2022 financial results, clinical progress, and operational updates, including interim data from BA3011 in sarcoma.
BioAtla reported its 2021 financial results, clinical milestones, and pipeline progress, including updates on BA3011, BA3021, and BA3071.
BioAtla entered into a collaboration with Bristol Myers Squibb to investigate BA3011 and BA3021 in combination with Opdivo in solid tumors.
Discussion of the development of CAB antibodies that can be activated or inactivated under physiological conditions for cancer therapy.